Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Calithera Biosciences, Inc. (CALA) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Calithera Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1496671.
Total stock buying since 2014: $54,170,741.
Total stock sales since 2014: $23,142,834.
Total stock option exercises since 2014: $639,030.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 121,333 | $46,834 | 0 | $0 |
| 2021 | 400,000 | $341,400 | 130,000 | $111,637 | 0 | $0 |
| 2020 | 0 | $0 | 2,294,066 | $13,780,438 | 0 | $0 |
| 2019 | 2,820,127 | $7,894,955 | 6,252 | $37,828 | 37,985 | $63,758 |
| 2018 | 0 | $0 | 1,565 | $9,405 | 65,695 | $128,563 |
| 2017 | 487,804 | $4,999,991 | 584,172 | $9,150,308 | 22,070 | $39,725 |
| 2016 | 500,000 | $1,575,000 | 0 | $0 | 73,820 | $119,945 |
| 2015 | 369,394 | $2,092,142 | 970 | $6,384 | 182,557 | $253,598 |
| 2014 | 3,781,700 | $37,267,253 | 0 | $0 | 6,797 | $33,441 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-01 | 0 | $0 | 121,333 | $46,834 | 0 | $0 |
| 2021-11 | 400,000 | $341,400 | 130,000 | $111,637 | 0 | $0 |
| 2020-12 | 0 | $0 | 2,447 | $14,682 | 0 | $0 |
| 2020-05 | 0 | $0 | 2,283,598 | $13,701,588 | 0 | $0 |
| 2020-04 | 0 | $0 | 5,000 | $40,000 | 0 | $0 |
| 2020-02 | 0 | $0 | 3,021 | $24,168 | 0 | $0 |
| 2019-12 | 0 | $0 | 3,021 | $18,126 | 0 | $0 |
| 2019-11 | 320,442 | $1,183,928 | 0 | $0 | 0 | $0 |
| 2019-10 | 2,396,485 | $6,310,611 | 0 | $0 | 0 | $0 |
| 2019-06 | 103,200 | $400,416 | 417 | $2,502 | 37,985 | $63,758 |
| 2019-05 | 0 | $0 | 416 | $2,496 | 0 | $0 |
| 2019-04 | 0 | $0 | 416 | $2,633 | 0 | $0 |
| 2019-03 | 0 | $0 | 1,982 | $12,071 | 0 | $0 |
| 2018-10 | 0 | $0 | 1,565 | $9,405 | 0 | $0 |
| 2018-04 | 0 | $0 | 0 | $0 | 16,810 | $8,068 |
| 2018-03 | 0 | $0 | 0 | $0 | 33,790 | $89,204 |
| 2018-02 | 0 | $0 | 0 | $0 | 15,095 | $31,291 |
| 2017-12 | 0 | $0 | 0 | $0 | 22,070 | $39,725 |
| 2017-09 | 0 | $0 | 576,000 | $9,008,100 | 0 | $0 |
| 2017-07 | 0 | $0 | 6,372 | $116,808 | 0 | $0 |
| 2017-05 | 0 | $0 | 650 | $10,400 | 0 | $0 |
| 2017-03 | 487,804 | $4,999,991 | 1,150 | $15,000 | 0 | $0 |
| 2016-12 | 0 | $0 | 0 | $0 | 32,100 | $57,779 |
| 2016-11 | 500,000 | $1,575,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-01-27 | Pakianathan Deepika (Director) | Sale | 121,333 | .39 | 46,834 |
| 2021-11-11 | Orford Keith (Director) | Sale | 48,190 | .88 | 42,407 |
| 2021-11-10 | Orford Keith (Director) | Sale | 30,000 | .86 | 25,710 |
| 2021-11-10 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Buy | 100,000 | .85 | 84,700 |
| 2021-11-10 | Drachman Jonathan G (Director) | Buy | 200,000 | .86 | 172,000 |
| 2021-11-10 | Molineaux Susan (PRESIDENT & CEO) | Buy | 100,000 | .85 | 84,700 |
| 2021-11-09 | Orford Keith (Director) | Sale | 51,810 | .84 | 43,520 |
| 2020-12-16 | Orford Keith (Chief Medical Officer) | Sale | 2,447 | 6.00 | 14,682 |
| 2020-05-21 | Lampert Mark N | Sale | 2,283,598 | 6.00 | 13,701,588 |
| 2020-04-15 | Wong Stephanie (SR. VP, FINANCE & SECRETARY) | Sale | 5,000 | 8.00 | 40,000 |
| 2020-02-20 | Orford Keith (Chief Medical Officer) | Sale | 3,021 | 8.00 | 24,168 |
| 2019-12-23 | Orford Keith (Chief Medical Officer) | Sale | 3,021 | 6.00 | 18,126 |
| 2019-11-20 | Lampert Mark N | Buy | 191,954 | 3.91 | 750,924 |
| 2019-11-14 | Lampert Mark N | Buy | 128,488 | 3.37 | 433,004 |
| 2019-10-30 | Lampert Mark N | Buy | 797,508 | 2.70 | 2,153,271 |
| 2019-10-29 | Lampert Mark N | Buy | 1,598,977 | 2.60 | 4,157,340 |
| 2019-06-25 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Buy | 51,600 | 3.88 | 200,208 |
| 2019-06-25 | Molineaux Susan (PRESIDENT AND CEO) | Buy | 51,600 | 3.88 | 200,208 |
| 2019-06-24 | Sjogren Eric (SR. VP, DRUG DISCOVERY) | Option Ex | 21,739 | .96 | 20,869 |
| 2019-06-19 | Wong Stephanie (SR. VP, FINANCE & SECRETARY) | Option Ex | 10,000 | 2.64 | 26,400 |
| 2019-06-17 | Parlati Francesco (VP, RESEARCH) | Option Ex | 6,246 | 2.64 | 16,489 |
| 2019-06-17 | Orford Keith (Chief Medical Officer) | Sale | 417 | 6.00 | 2,502 |
| 2019-05-22 | Orford Keith (Chief Medical Officer) | Sale | 416 | 6.00 | 2,496 |
| 2019-04-15 | Orford Keith (Chief Medical Officer) | Sale | 416 | 6.33 | 2,633 |
| 2019-03-15 | Orford Keith (Chief Medical Officer) | Sale | 417 | 6.43 | 2,681 |
| 2019-03-11 | Orford Keith (Chief Medical Officer) | Sale | 1,565 | 6.00 | 9,390 |
| 2018-10-15 | Orford Keith (SR. VP, CLINICAL DEVELOPMENT) | Sale | 313 | 6.05 | 1,893 |
| 2018-10-11 | Orford Keith (SR. VP, CLINICAL DEVELOPMENT) | Sale | 1,252 | 6.00 | 7,512 |
| 2018-04-03 | Sjogren Eric (SR. VP, DRUG DISCOVERY) | Option Ex | 16,810 | .48 | 8,068 |
| 2018-03-02 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Option Ex | 6,798 | 2.64 | 17,946 |
| 2018-03-02 | Molineaux Susan (PRESIDENT AND CEO) | Option Ex | 26,992 | 2.64 | 71,258 |
| 2018-02-23 | Wong Stephanie (SR VP, FINANCE AND SECRETARY) | Option Ex | 10,000 | 2.64 | 26,400 |
| 2018-02-20 | Parlati Francesco (VP, RESEARCH) | Option Ex | 5,095 | .96 | 4,891 |
| 2017-12-05 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Option Ex | 9,202 | 1.80 | 16,563 |
| 2017-12-05 | Molineaux Susan (PRESIDENT AND CEO) | Option Ex | 12,868 | 1.80 | 23,162 |
| 2017-09-28 | Gross Phillip | Sale | 38,000 | 15.50 | 589,000 |
| 2017-09-27 | Gross Phillip | Sale | 186,000 | 15.59 | 2,899,740 |
| 2017-09-26 | Gross Phillip | Sale | 352,000 | 15.68 | 5,519,360 |
| 2017-07-17 | Orford Keith (SR. VP, CLINICAL DEVELOPMENT) | Sale | 2,120 | 18.31 | 38,823 |
| 2017-07-17 | Wong Stephanie (VP, FINANCE AND SECRETARY) | Sale | 3,552 | 18.41 | 65,385 |
| 2017-07-06 | Hecht Curtis (SVP, BUS. & CORP. DEVELOPMENT) | Sale | 700 | 18.00 | 12,600 |
| 2017-05-19 | Hecht Curtis (SVP, BUS. & CORP. DEVELOPMENT) | Sale | 650 | 16.00 | 10,400 |
| 2017-03-22 | Gross Phillip | Buy | 487,804 | 10.25 | 4,999,991 |
| 2017-03-13 | Hecht Curtis (SVP, BUS. & CORP. DEVELOPMENT) | Sale | 600 | 14.00 | 8,400 |
| 2017-03-02 | Hecht Curtis (See Remarks) | Sale | 550 | 12.00 | 6,600 |
| 2016-12-19 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Option Ex | 10,167 | 1.80 | 18,300 |
| 2016-12-19 | Molineaux Susan (PRESIDENT AND CEO) | Option Ex | 21,933 | 1.80 | 39,479 |
| 2016-11-16 | Gross Phillip | Buy | 500,000 | 3.15 | 1,575,000 |
| 2016-07-20 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Option Ex | 12,335 | 1.80 | 22,203 |
| 2016-07-20 | Molineaux Susan (PRESIDENT AND CEO) | Option Ex | 29,385 | 1.36 | 39,963 |
| 2015-12-29 | Bennett Mark K (SR. VP, RESEARCH) | Option Ex | 10,413 | 1.14 | 11,870 |
| 2015-12-21 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Option Ex | 10,167 | 1.80 | 18,300 |
| 2015-12-21 | Molineaux Susan (PRESIDENT AND CEO) | Option Ex | 27,825 | 1.14 | 31,720 |
| 2015-11-16 | Hecht Curtis (VP, BUS. & CORP. DEVELOPMENT) | Sale | 970 | 6.58 | 6,384 |
| 2015-09-23 | Gross Phillip | Buy | 40,168 | 6.07 | 243,779 |
| 2015-09-22 | Gross Phillip | Buy | 66,800 | 6.00 | 400,866 |
| 2015-09-04 | Gross Phillip | Buy | 2,300 | 5.95 | 13,685 |
| 2015-09-03 | Gross Phillip | Buy | 88,000 | 5.93 | 521,840 |
| 2015-08-28 | Gross Phillip | Buy | 42,700 | 5.57 | 237,625 |
| 2015-08-27 | Gross Phillip | Buy | 97,168 | 5.39 | 523,541 |
| 2015-08-26 | Gross Phillip | Buy | 32,258 | 4.67 | 150,806 |
| 2015-08-20 | Hecht Curtis (VP, BUS. & CORP. DEVELOPMENT) | Option Ex | 2,000 | 2.64 | 5,280 |
| 2015-07-14 | Waddill William D. (SR. VP & CFO) | Option Ex | 13,125 | 2.64 | 34,650 |
| 2015-07-13 | Molineaux Christopher (SR. VP, DEVELOPMENT) | Option Ex | 24,375 | 1.80 | 43,875 |
| 2015-07-13 | Molineaux Susan (PRESIDENT AND CEO) | Option Ex | 76,287 | 1.14 | 86,967 |
| 2015-07-08 | Bennett Mark K (SR. VP, RESEARCH) | Option Ex | 18,365 | 1.14 | 20,936 |
| 2014-12-16 | Waddill William D. (SENIOR VP & CFO) | Option Ex | 6,797 | 4.92 | 33,441 |
| 2014-10-15 | Gross Phillip | Buy | 38,000 | 7.03 | 266,950 |
| 2014-10-14 | Gross Phillip | Buy | 55,000 | 7.00 | 384,725 |
| 2014-10-13 | Gross Phillip | Buy | 88,700 | 6.94 | 615,578 |
| 2014-10-07 | Atv Associates Viii, L.l.c. (10% Owner) | Buy | 300,000 | 10.00 | 3,000,000 |
| 2014-10-07 | Morgenthaler Venture Partners Ix Lp (10% Owner) | Buy | 350,000 | 10.00 | 3,500,000 |
| 2014-10-07 | Christoffersen Ralph E (Director) | Buy | 350,000 | 10.00 | 3,500,000 |
| 2014-10-07 | George Jean (Director) | Buy | 300,000 | 10.00 | 3,000,000 |
| 2014-10-07 | Pakianathan Deepika (Director) | Buy | 1,000,000 | 10.00 | 10,000,000 |
| 2014-10-01 | Gross Phillip | Buy | 800,000 | 10.00 | 8,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of CALA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Calithera Biosciences, Inc. (symbol CALA, CIK number 1496671) see the Securities and Exchange Commission (SEC) website.